Cargando…

Liquid Biopsy, ctDNA Diagnosis through NGS

Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains information of genetic alterations. Compared to tissue...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chen, Liu, Xuzhu, Zheng, Bingyi, Ke, Rongqin, Tzeng, Chi-Meng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468354/ https://www.ncbi.nlm.nih.gov/pubmed/34575039 http://dx.doi.org/10.3390/life11090890

Ejemplares similares

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer
por: Escudero, Laura, et al.
Publicado: (2021)

Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma
por: Friedman, Joshua S, et al.
Publicado: (2022)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
por: Lim, Minji, et al.
Publicado: (2018)

ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
por: Neumann, Martin H.D., et al.
Publicado: (2018)

Establishing the Clinical Utility of ctDNA Analysis for Diagnosis, Prognosis, and Treatment Monitoring of Retinoblastoma: The Aqueous Humor Liquid Biopsy
por: Xu, Liya, et al.
Publicado: (2021)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers
por: Xie, Jianjiang, et al.
Publicado: (2023)

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer
por: Semenkovich, Nicholas P., et al.
Publicado: (2023)

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer
por: Semenkovich, Nicholas P., et al.
Publicado: (2023)

Detection of ctDNA with Personalized Molecular Barcode NGS and Its Clinical Significance in Patients with Early Breast Cancer
por: Yoshinami, Tetsuhiro, et al.
Publicado: (2020)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome
por: Vendrell, Julie A., et al.
Publicado: (2021)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma
por: Li, Dan, et al.
Publicado: (2021)

Nosological and Theranostic Approach to Vascular Malformation through cfDNA NGS Liquid Biopsy
por: Serio, Viola Bianca, et al.
Publicado: (2022)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation
por: Carvalho, Ângela, et al.
Publicado: (2021)

The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review
por: Kopystecka, Agnieszka, et al.
Publicado: (2023)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA)
por: Gasparello, Jessica, et al.
Publicado: (2018)

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review
por: Wang, Wenwen, et al.
Publicado: (2023)

Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data
por: Zhao, Songchen, et al.
Publicado: (2021)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays
por: Hallermayr, Ariane, et al.
Publicado: (2023)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Correction to: Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
por: Papadopoulou, Eirini, et al.
Publicado: (2019)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_71ib42sidblc2h9dnp3uvbgnlh